High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
By J. Kirkwood, J. Ibrahim, V. Sondak, J. Richards, L. Flaherty, M. Ernstoff, T. Smith, U. Rao, M. Steele, R. Blum. Journal of Clinical Oncology, 2000
872 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/52e3f76e7436022ababd40d3f5af980ff5a4f422
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- The Power Prior: Theory and Applications (2015, methodology): “The ECOG trial E1690 was a three-arm phase III clinical trial and had treatment arms of high-dose IFN, low-dose IFN, and observation [67].”
- A flexible model for survival data with a cure rate: a Bayesian approach (2011, background): “The data were taken from [12] (see also [14]).”
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “A number of prospective randomised trials have investigated adjuvant treatment with low, intermediate and high doses of interferon-α (IFN-α) [16, 17].”
- Cytokines in Cancer Immunotherapy (2011, result): “While these trials initially showed improvement in both relapse-free survival and overall survival, subsequent long term follow-up data led to the finding that with longer follow-up time, the tails of the curves for relapse-free and particularly overall survival no longer demonstrated significant be”